← Search & browse all drugs
ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates
amivantamab
L01FX18
Forms & Strengths
- 400 mg/20 mL (20 mg/mL) single-dose vial
- 800 mg/40 mL (20 mg/mL) single-dose vial
- Intravenous injection
Adult Dosing
- Initial dose: 1050 mg on day 1, 350 mg on day 2, 420 mg on day 3, then 420 mg every 2 weeks
- Subsequent doses: 420 mg intravenously every 2 weeks
- Dose reduction and interruption guidelines available
Pediatric Dosing
- Not established for patients less than 18 years of age
Indications
- Treatment of adult patients with non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations
- Locally advanced or metastatic disease
Mechanism of Action
- Bispecific antibody that targets EGFR and mesenchymal-epithelial transition factor (MET)
- Blocks signaling pathways involved in cell growth and proliferation
Contraindications
- Hypersensitivity to amivantamab or any component of the product
Adverse Reactions
- Infusion-related reactions (e.g., chills, dyspnea, nausea)
- Rash, fatigue, and decreased appetite
- Interstitial lung disease, pneumonitis, and other pulmonary toxicities
Drug Interactions
- None specifically identified, but caution advised with concomitant use of other EGFR inhibitors
Curated Content: Needs Vetting Before Put to Clinical Use